Sachs Associates 10 Annual European Life Sciences CEO Forum & Exhibition, 2017

Santa Monica, CA, 26 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition being held on 6th-7th March, 2017 at the Hilton Zurich Airport Hotel, Switzerland.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.

UCLA Spinout Trethera Trials Novel DNA Metabolism Combination

25 January 2017
SCRIP

Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach.

Read Article

Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies

Santa Monica, CA and Alachua, FL, January 5, 2017 – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis.

Read full press release

9th Annual Biotech Showcase 2017

Santa Monica, CA, 4 January 2017 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Biotech Showcase 2017, San Francisco, USA, 9th-11th January 2017. The Company’s targeted metabolic pathway therapy approach involves using a rationally-designed combination of two or three drugs from the very start of cancer treatment.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.

Trethera Corporation to present at BIO Investor Forum

Beverly Hills, CA, 6 October 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be presenting at the BIO Investor Forum, San Francisco, USA, 18-19 October 2016.

Johanna Holldack, Trethera’s CEO, will be giving a Company Presentation on Tuesday, 18 October 2016 at 15:00 in the Yorkshire presentation room.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.

Trethera Corporation to present at BioPharm America

Beverly Hills, CA, 6 September 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be giving a Company Presentation at BioPharm America, Boston, USA, 13-15 September 2016.

For more information on Trethera’s presentations or for media enquiries, please contact trethera@instinctif.com.

Trethera Appoints Lynne Rollins as new Chief Financial Officer

Beverly Hills, CA, 21 July 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced the appointment of Lynne Rollins as its new Chief Financial Officer (CFO). The appointment is effective immediately.

Lynne brings over 35 years’ of experience in the healthcare industry across finance, strategic planning and business development. Following senior positions at Baxter Healthcare Corporation, Lynne has advised over 30 startup medical device and biopharmaceutical companies including HighLife Medical, Syndax Pharmaceuticals and Calixa Therapeutics. Lynne has a B.S. in Finance from California State University and a MBA from Pepperdine University.

Read full press release

Trethera Corporation strengthens team with two new hires

Beverly Hills, CA, 20 June 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors announces the appointments of Dr. Neil Bajpayee and Shailaja Srinagesh to the positions of Associate Director of Scientific Affairs and Drug Development Project Manager respectively.

Read full press release

Trethera and UCLA enter into research collaboration agreement for the development of novel anti-cancer agents

Beverly Hills, CA, 23 March 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced that they have entered into a collaborative research agreement with the University of California, Los Angeles (UCLA) to develop novel anti-cancer agents.

Under the formal agreement, UCLA and Trethera will undertake collaborative research activities intended to support Trethera’s technology platform which is based on the pharmacologic blockade of DNA synthesis and DNA repair pathways.

Dr. Holldack, CEO of Trethera, said: “We believe that our drug development capabilities combined with the scientific expertise of UCLA’s investigators in cancer biology, will produce a synergistic collaboration purposed to advance new therapeutics into clinical development.”

Read full press release

Trethera attending the 8th Annual Biotech Showcase 2016

Beverly Hills, CA, 4 January 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Biotech Showcase, San Francisco, USA, 11th-13th January 2016. The Company’s targeted metabolic pathway therapy approach involves using a rationally-designed combination of two or three drugs from the very start of cancer treatment.